Physician profile
Thomas E Daglish
NPI 1982688206
$319.06
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $285 · 2020: $34.01.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $100.24 | 2019 | |
| Pfizer INC. | $29.21 | 2019 | |
| Merck Sharp & Dohme LLC | $26.84 | 2019 | |
| Amarin Pharma, INC. | $23.94 | 2019 | |
| Sanofi-Aventis U.S. LLC | $22.37 | 2019 | |
| Amgen INC. | $22.10 | 2019 | |
| Glaxosmithkline, LLC. | $21.65 | 2019 | |
| Antares Pharma, INC. | $19.47 | 2019 | |
| Sanofi Pasteur INC. | $19.23 | 2019 | |
| Hologic Sales and Service, LLC | $17.54 | 2020 | |
| Novo Nordisk INC | $16.47 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Daglish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.